Research · Sep 3, 2026
[SNY] Sanofi Thesis 2026: Dupixent Franchise Drives Post-Consumer Health Spinoff Cycle
Sanofi SA (NASDAQ: SNY) FY2025 revenue ~€42-44B (+5-9%) with business EPS ~€7.20-7.80 reflecting continued Dupixent (dupilumab) ~€13-14B revenue (~30% revenue mix; +20%+ growth) plus selected post-October 2024 Opella consumer healthcare spin-off completion (~€16B aggregate transaction value via CD&R 50% stake purchase) plus refocus on biopharma + vaccines under continued CEO Paul Hudson (~6-year tenure since September 2019). Global biopharmaceutical leader with operations across pharmaceuticals + vaccines + selected continued consumer healthcare (~48% retained Opella stake) in ~100+ countries. Founded 1973 as Sanofi via Société Nationale Elf Aquitaine pharmaceuticals subsidiary creation; selected post-1999 ~$30B Sanofi-Synthélabo merger; selected post-August 2004 ~$66B Aventis acquisition creating Sanofi-Aventis; selected post-2009 rebranding back to Sanofi; selected post-April 2011 ~$20B Genzyme acquisition (rare diseases + multiple sclerosis); selected post-2018 ~$11B Bioverativ acquisition (hemophilia); selected post-2018 ~$4.8B Ablynx acquisition; selected post-2020 ~$3.7B Principia Biopharma acquisition (autoimmune); selected post-2020 ~$3.4B Translate Bio mRNA acquisition; selected post-October 2024 Opella consumer healthcare spin-off announcement (~€16B aggregate transaction value). Headquartered in Paris France; ~91,000+ employees globally with ~€42-44B revenue. Three primary reporting segments: Pharmaceuticals ~75% revenue (~€32B — Specialty Care including Dupixent + immunology + rare diseases + multiple sclerosis + oncology; General Medicines including Lantus + Toujeo diabetes + cardiovascular + selected other), Vaccines ~15% (~€6-7B — influenza Fluzone + Beyfortus RSV + Adacel pertussis + Menquadfi meningococcal + travel + endemic vaccines), Consumer Healthcare (Opella) ~10% (~€5B — post-October 2024 spin-off retained ~48%; products include Allegra + Doliprane + selected over-the-counter analgesics). Dupixent franchise leadership: ~€13-14B revenue FY2025 (+20%+ YoY; ~30% revenue mix); 6 major indications: atopic dermatitis (2017) + asthma (2018) + chronic rhinosinusitis with nasal polyposis (2019) + eosinophilic esophagitis (2022) + prurigo nodularis (2022) + COPD with type 2 inflammation (September 2024 FDA approval; first biologic approved for COPD globally); ~50-50 profit share with Regeneron; peak sales potential ~€20B+; FY2026 expansion: bullous pemphigoid + chronic spontaneous urticaria pivotal trials. Opella consumer healthcare spin-off: October 2024 announced ~€16B aggregate transaction value spin-off to CD&R (CD&R purchasing 50% stake; Sanofi retaining 48% + ~2% retained employee shares); ~€8B+ proceeds to Sanofi; expected close H1 2025; selected ~€2-3B incremental FY2025-2026 buyback. Vaccines + Beyfortus RSV: Fluzone influenza ~€3B+; Beyfortus (nirsevimab) RSV ~€1-2B FY2025 (~50-50 profit share with AstraZeneca; FDA approved July 2023; ~70-80% US RSV prevention market share); Adacel + Menquadfi + selected travel + endemic ~€2-3B aggregate. CEO Paul Hudson since September 2019 (succeeded Olivier Brandicourt CEO 2015-September 2019 retired; Hudson ex-Novartis Pharmaceuticals President 2016-2019 + ~30-year pharma career). Capital return: ~€3.92-4.02 annual dividend FY2025 (~30+ year continuous track); ~€2-3B aggregate FY2024-2025 buybacks; investment-grade A1/AA credit ratings; selected post-Opella spin-off net cash position ~€5-7B. FY2026 thesis: Dupixent franchise expansion + Opella spin-off close + accelerated buyback + immunology pipeline + Beyfortus RSV growth. Risks: Dupixent biosimilar erosion ~2031 patent expiry, pipeline failures (itepekimab COPD + Tolebrutinib MS), vaccines competition (Pfizer Abrysvo + GSK Arexvy), US Inflation Reduction Act drug price negotiation, Opella spin-off execution.